学术周报 · IF≥10

胆胰外科领域文献阅读汇编

2026年第39周 (2026-09-23) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
收录论文
8
临床研究
2
基础研究
6
IF≥20
4
IF 10-20
4
子领域
4
期刊种类
8
数据日期
2026-09-23

★本周 Top 10 高影响力文献

#论文期刊IF
1Restoration of aged liver regeneration by youthful systemic factors via LTβ-driven hepatocyte reprog...Journal of hepatologyIF 40.1
2Targeting RAS for Pancreatic Cancer Interception.Cancer discoveryIF 29.5
3Longitudinal Analysis of Matched Patient Biospecimens Reveals Neural Reprogramming of Cancer-Associa...Cancer researchIF 22.6
4Precision oncology in GI-cancers: Mechanisms of action, indications and ongoing strategies to overco...Seminars in cancer biologyIF 20.3
5Tripterine Liposome Exerts Antitumor and Immunomodulatory Effects in Pancreatic Ductal Adenocarcinom...MedCommIF 14.1
6Renal-clearable fluorescent probe for early detection of pancreatic cancer in living murine models.Science advancesIF 13.9
7Decoding neuro-tumor interactions in pancreatic cancer: mechanisms, immunosuppressive networks and t...Molecular biomedicineIF 13.0
8CRISPR-based diagnostics as a specificity layer for the early detection of pancreatic cancer.Cancer lettersIF 11.8

Ŧ期刊分布统计

期刊篇数IF
MedComm1IF 14.1
Journal of hepatology1IF 40.1
Cancer discovery1IF 29.5
Cancer research1IF 22.6
Seminars in cancer biology1IF 20.3
Cancer letters1IF 11.8
Science advances1IF 13.9
Molecular biomedicine1IF 13.0

1胰腺癌/胰十二指肠切除 (4篇)

临床研究 (1篇)

Cancer research IF 22.6 2026-9-21 PMID: 42765602
Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is a deadly disease with a complex tumor microenvironment (TME). Cytotoxic combination chemotherapy treatments are the mainstay of PDAC therapy, but patients rapidly develop chemoresistance, highlighting the need to elucidate how chemotherapy alters the TME and whether these changes drive chemoresistance. Here, we examined matched pre- and post-treatment tissue specimens using single-cell RNA-sequencing and found near-universal enrichment after treatment of axonal guidance genes in cancer-associated fibroblasts (CAFs). These neural CAFs were enriched near sites of perineural invasion, coinciding with regions of increased tumor cell proliferation, and were enriched in tumor areas distant from nerves after chemotherapy. Metastatic recurrent lesions had the highest prevalence of neural CAFs versus primary tumors and untreated metastases. Neural CAFs showed elevated non-canonical WNT mediators and axonal guidance genes, which complemented matching cognate binding partners in tumor epithelial cells, suggesting a role in tumor-stroma crosstalk. Additionally, in vitro studies revealed enrichment of axonal guidance genes in patient-derived CAF lines upon exposure to chemotherapy or tumor cells. Altogether, these findings implicate fibroblast-derived axonal-guidance genes in promoting PDAC invasion and point to a promising therapeutic target for this disease.
中文摘要:胰腺导管腺癌(PDAC)是胰腺癌最常见的亚型,是一种致死性疾病,具有复杂的肿瘤微环境(TME)。细胞毒性联合化疗是PDAC治疗的主要手段,但患者会迅速产生化疗耐药,这凸显出需要阐明化疗如何改变TME以及这些改变是否驱动化疗耐药。在此,我们使用单细胞RNA测序检测了配对的治疗前和治疗后组织标本,发现治疗后癌症相关成纤维细胞(CAF)中轴突导向基因几乎普遍富集。这些神经性CAF富集于神经周围侵犯部位附近,与肿瘤细胞增殖增加的区域重合,并且在化疗后富集于远离神经的肿瘤区域。与原发性肿瘤和未治疗的转移灶相比,转移性复发病灶中神经性CAF的患病率最高。神经性CAF表现出非经典WNT介质和轴突导向基因升高,这与肿瘤上皮细胞中匹配的同源结合伴侣互补,提示其在肿瘤-基质串扰中发挥作用。此外,体外研究显示,患者来源的CAF细胞系在暴露于化疗或肿瘤细胞后,轴突导向基因富集。总之,这些发现提示成纤维细胞来源的轴突导向基因促进PDAC侵袭,并指出一个有前景的该疾病治疗靶点。

基础研究 (3篇)

MedComm IF 14.1 2026-9-22 PMID: 42769546
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly aggressive phenotype and limited therapeutic options, primarily attributable to diagnostic delays and intrinsic chemotherapy resistance, thereby underscoring the critical need for the development of more effective therapeutic strategies. Tripterine (TP) is a natural compound with potent antitumor activity, but has shown limited clinical use due to its multi-organ toxicity. Here, we overcame this limitation by formulating TP into liposomes (TP-lipo). We evaluated the therapeutic potential of TP-lipo showing that TP-lipo exhibited antitumor activity in vitro (murine Pdx1-Cre/LSL-KrasG12D/+ /LSL-Trp53R172H/+ pancreatic cancer cells, KPC cells) and in vivo (PDAC mouse) models. TP-lipo reshaped the tumor immune microenvironment by promoting macrophage polarization toward the M1 phenotype, increasing the proportion of interferon-γ (IFN-γ)-secreting CD8+ T cells. In vitro, TP-lipo promoted IFN-γ and granzyme B production in CD8+ T cells, while TP-lipo-pretreated macrophages enhanced T-cell differentiation into cytotoxic T lymphocytes. Notably, combination therapy with TP-lipo and PD-1 antagonist exerted a synergistic antitumor effect and significantly prolonged median survival in PDAC-bearing mice. TP-lipo showed substantially lower toxicity than the free drug, highlighting its improved safety profile and therapeutic potential. Collectively, these findings suggest TP-lipo, particularly in combination with PD-1 blockade, as a promising therapeutic strategy for PDAC.
中文摘要:胰腺导管腺癌(PDAC)具有高度侵袭性的表型且治疗选择有限,主要归因于诊断延迟和内在的化疗耐药,因此亟需开发更有效的治疗策略。雷公藤红素(TP)是一种具有强效抗肿瘤活性的天然化合物,但由于其多器官毒性,临床应用受限。在本研究中,我们通过将TP制成脂质体(TP-lipo)克服了这一限制。我们评估了TP-lipo的治疗潜力,结果显示TP-lipo在体外(小鼠Pdx1-Cre/LSL-KrasG12D/+ /LSL-Trp53R172H/+胰腺癌细胞,KPC细胞)和体内(PDAC小鼠)模型中均表现出抗肿瘤活性。TP-lipo通过促进巨噬细胞向M1表型极化、增加分泌干扰素-γ(IFN-γ)的CD8+ T细胞比例,重塑了肿瘤免疫微环境。在体外,TP-lipo促进CD8+ T细胞产生IFN-γ和颗粒酶B,而经TP-lipo预处理的巨噬细胞增强T细胞向细胞毒性T淋巴细胞分化。值得注意的是,TP-lipo与PD-1拮抗剂联合治疗发挥了协同抗肿瘤作用,并显著延长了荷PDAC小鼠的中位生存期。TP-lipo的毒性显著低于游离药物,突显了其改善的安全性特征和治疗潜力。总之,这些发现表明TP-lipo,尤其是与PD-1阻断联合,是PDAC的一种有前景的治疗策略。
Cancer discovery IF 29.5 2026-9-22 PMID: 42770704
Multiple strategies to target RAS are now available to treat pancreatic cancer. As pancreatic precancers also have KRAS mutations, these tools hold great promise for cancer interception.
中文摘要:针对RAS的多种策略现已可用于治疗胰腺癌。由于胰腺癌前病变也具有KRAS突变,这些工具在癌症拦截方面具有巨大前景。
Molecular biomedicine IF 13.0 2026-9-17 PMID: 42749962
Pancreatic cancer is one of the most lethal digestive system malignancies worldwide, characterized by insidious onset, limited early detection approaches and extremely poor long-term prognosis. It comprises multiple histological subtypes, among which pancreatic ductal adenocarcinoma (PDAC) represents the most prevalent exocrine neoplasm and accounts for the vast majority of all pancreatic cancer cases. Perineural invasion (PNI) stands as one of the defining biological hallmarks of PDAC. Detected in 80%-100% of PDAC patients, PNI serves as an independent adverse prognostic factor that drives local recurrence, distant metastasis, and resistance to both chemotherapy and immunotherapy. Historically regarded as a passive route for tumor dissemination, PNI is now recognized as a complex, multicellular process involving bidirectional crosstalk between cancer cells, nerve fibers, stromal cells, and immune components within the tumor microenvironment. This review dissects the molecular mechanisms underlying neuro-tumor interactions and proposes a unified four-stage mechanistic model of PNI, encompassing mutual chemotaxis between tumors and nerves, adhesion and invasion at the tumor-nerve interface, extracellular matrix remodeling, and neural plasticity alterations. Notably, we define the perineural invasion microenvironment as a neuro-immune privileged sanctuary, and delineate its multicellular composition and pathological consequences based on current research advances. Furthermore, we summarize potential therapeutic strategies targeting the neuro-immune-tumor axis and ongoing clinical trials, discuss key translational challenges, and highlight the transformative applications of multi-omics technologies and artificial intelligence in PNI diagnosis, mechanistic discovery, and therapeutic optimization. This work provides a comprehensive theoretical framework for understanding PNI mechanisms and guides future translational research and precision therapy development for pancreatic cancer.
中文摘要:胰腺癌是全球范围内最致命的消化系统恶性肿瘤之一,具有起病隐匿、早期检测手段有限和长期预后极差的特点。它包含多种组织学亚型,其中胰腺导管腺癌(PDAC)是最常见的胰腺外分泌肿瘤,占所有胰腺癌病例的绝大多数。神经周围侵犯(PNI)是PDAC的标志性生物学特征之一。在80%-100%的PDAC患者中可检测到PNI,它作为独立的不良预后因素,促进局部复发、远处转移,并导致化疗和免疫治疗耐药。历史上曾被视为肿瘤播散的被动途径,如今PNI被认为是一个复杂、多细胞参与的过程,涉及肿瘤微环境中癌细胞、神经纤维、基质细胞和免疫成分之间的双向串扰。本综述剖析了神经-肿瘤相互作用的分子机制,并提出PNI的统一四阶段机制模型,包括肿瘤与神经之间的相互趋化、肿瘤-神经界面的黏附和侵袭、细胞外基质重塑以及神经可塑性改变。值得注意的是,我们将神经周围侵犯微环境定义为神经-免疫豁免庇护所,并基于当前研究进展阐明其多细胞组成和病理后果。此外,我们总结了靶向神经-免疫-肿瘤轴的潜在治疗策略及正在进行的临床试验,讨论了关键的转化挑战,并强调了多组学技术和人工智能在PNI诊断、机制发现和治疗优化中的变革性应用。这项工作为理解PNI机制提供了全面的理论框架,并指导胰腺癌未来的转化研究和精准治疗开发。

2胰腺癌 (2篇)

临床研究 (1篇)

Cancer letters IF 11.8 2026-9-18 PMID: 42759923
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, largely because early-stage symptoms are non-specific and diagnosis is often delayed. Although liquid biopsies (LBs) offer a promising non-invasive strategy for early detection, their clinical translation is hindered by substantial analytical limitations. This review examines the current landscape of nucleic acid-based liquid biopsy biomarkers for PDAC detection. We evaluate key limitations of established diagnostic methodologies, including next-generation sequencing (NGS) and droplet digital PCR (ddPCR). In complex biofluids, these approaches may be confounded by background signal and amplification artifacts, particularly when applied for the detection of ultra-rare targets. To address this diagnostic gap, we discuss the role of CRISPR-based biosensing and bioassay not as a replacement but as an additional specificity layer within existing diagnostic workflows. In this framework, CRISPR technologies can act as sequence-specific molecular filters that introduce an active post-amplification validation step. Although pre-analytical limitations remain to be fully characterized, integrating CRISPR into the diagnostic workflow may contribute to a rapid, cost-effective, and highly specific framework for the early detection of PDAC.
中文摘要:胰腺导管腺癌(PDAC)仍是一种高度致命的恶性肿瘤,主要原因在于早期症状缺乏特异性且诊断常被延迟。尽管液体活检(LB)为早期检测提供了一种有前景的无创策略,但其临床转化受到显著分析局限性的阻碍。本综述审视了用于PDAC检测的核酸类液体活检生物标志物的当前图景。我们评估了现有诊断方法的关键局限性,包括下一代测序(NGS)和微滴数字PCR(ddPCR)。在复杂生物体液中,这些方法可能受到背景信号和扩增伪影的干扰,尤其是在用于检测超罕见靶标时。为弥补这一诊断缺口,我们讨论了基于CRISPR的生物传感和生物测定所发挥的作用,即并非作为替代,而是作为现有诊断工作流程中的额外特异性层。在此框架中,CRISPR技术可作为序列特异性分子过滤器,引入主动的扩增后验证步骤。尽管分析前局限性仍有待充分表征,将CRISPR整合到诊断工作流程中,可能有助于构建一个快速、经济且高度特异的PDAC早期检测框架。

基础研究 (1篇)

Science advances IF 13.9 2026-9-16 PMID: 42748261
Pancreatic cancer (PC) is a highly aggressive and lethal malignancy with extremely poor patient survival rates. The lack of biomarkers and deep tissue detection barriers has presented long-standing and unsolved issues, severely hindering the early diagnosis of PC even in living rodent models. Here, we report a renal-clearable leucine aminopeptidase (LAP)-activatable fluorescence probe, overturning the probe's pharmacokinetics from the liver to kidney pathway (90% of the injection dosage). This strategy reduces interference in the liver and enables LAP as a biomarker for PC detection in murine models. After in situ response with LAP in the pancreas, renal-clearable fluorogenic fragments could be efficiently excreted into the urine, thus addressing the depth barriers of PC. Our strategy has resolved the lack of biomarkers and deep tissue detection barriers in early PC detection in murine models, which would greatly expand the bioanalytical toolbox for PC identification, further enabling the efficient screening of PC drugs at the animal level and the exploration of diagnostic methods for PC.
中文摘要:胰腺癌(PC)是一种高度侵袭性且致死性的恶性肿瘤,患者生存率极低。生物标志物缺乏和深部组织检测障碍长期存在且尚未解决,严重阻碍了胰腺癌的早期诊断,即使在活体啮齿动物模型中也是如此。在此,我们报道了一种可经肾脏清除的亮氨酸氨肽酶(LAP)激活型荧光探针,将探针的药代动力学从肝脏途径逆转为肾脏途径(占注射剂量的90%)。该策略减少了肝脏干扰,并使LAP可作为小鼠模型中胰腺癌检测的生物标志物。在与胰腺中的LAP发生原位响应后,可经肾脏清除的产荧光片段能够有效排泄至尿液中,从而解决了胰腺癌的深度障碍。我们的策略解决了小鼠模型早期胰腺癌检测中生物标志物缺乏和深部组织检测障碍的问题,将极大拓展用于胰腺癌识别的生物分析工具箱,进一步实现在动物层面高效筛选胰腺癌药物,并探索胰腺癌诊断方法。

3肝移植 (1篇)

基础研究 (1篇)

Journal of hepatology IF 40.1 2026-9-22 PMID: 42772698
The regenerative capacity of the liver decreases with age, limiting surgical options for elderly patients. While youthful systemic factors can reverse liver aging, the underlying mediators remain unclear. This study aimed to investigate the systemic factors and cellular mechanisms that promote aged liver regeneration. We retrospectively analyzed a split liver transplantation (SLT) cohort (n=36 pairs) to evaluate human graft regeneration. In animal models, 18-month-old and 2-month-old mice were subjected to heterochronic parabiosis, a procedure in which two animals of different ages were surgically connected to share a common circulation, followed by 70% partial hepatectomy. Single-cell transcriptomic profiling and lineage tracing were used to map hepatocyte dynamics. To elucidate the underlying mechanisms, hepatocyte-specific lymphotoxin β receptor (Ltbr) knockout and in vivo B-cell manipulations were employed to validate the key effectors and downstream signaling. In the SLT cohort, grafts in young recipients exhibited a significantly higher liver regeneration ratio than those in aged recipients. In murine experiments, heterochronic parabiosis significantly accelerated regeneration in aged mice. Single-cell transcriptomic profiling and lineage-tracing analyses revealed that aged periportal hepatocytes underwent transient somatic reprogramming to aid hepatocyte repopulation. Mechanistically, we discovered that this reprogramming was driven by young parabiont-derived lymphotoxin β (LTβ)/LTBR signaling. Further analysis identified young B cells as critical effectors, as these cells exhibited increased liver infiltration and elevated LTβ expression to promote hepatocyte reprogramming. Moreover, agonistic LTBR antibody administration successfully induced periportal reprogramming and accelerated aged liver regeneration. Young B-cell-derived LTβ promotes aged liver regeneration by promoting the transient somatic reprogramming of periportal hepatocytes via LTβ/LTBR signaling. Our study highlights the therapeutic potential of LTβ-based strategies to increase regeneration in aging populations. The regenerative capacity of the liver decreases with age, limiting the utilization of elderly grafts. This study demonstrates that youthful systemic circulation rejuvenates aged liver regeneration through young B-cell-derived lymphotoxin β (LTβ), which induces the transient somatic reprogramming of periportal hepatocytes via LTβ/LTBR signaling. These findings are highly relevant to transplant surgeons, hepatologists, and aging researchers. Practically, short-term pharmacological LTBR agonism could be utilized by clinicians to therapeutically "pre-condition" elderly donor livers or enhance post-hepatectomy regeneration in older patients. Furthermore, our work establishes heterochronic transplantation as a powerful clinical research platform to investigate anti-aging mechanisms and rejuvenation strategies across solid organs.
中文摘要:肝脏的再生能力随年龄增长而下降,限制了老年患者的手术选择。虽然年轻的全身性因素可以逆转肝脏衰老,但其潜在介导因素仍不清楚。本研究旨在探讨促进老年肝脏再生的全身性因素和细胞机制。我们回顾性分析了一个劈离式肝移植(SLT)队列(n=36对),以评估人类移植肝的再生。在动物模型中,对18月龄和2月龄小鼠进行异时联体共生,这是一种将两只不同年龄动物通过手术连接以共享共同循环的操作,随后进行70%部分肝切除术。采用单细胞转录组分析和谱系追踪来描绘肝细胞动态。为阐明潜在机制,采用肝细胞特异性淋巴毒素β受体(Ltbr)敲除和体内B细胞操作,以验证关键效应因子和下游信号。在SLT队列中,年轻受者中的移植肝显示出显著高于老年受者的肝脏再生比例。在小鼠实验中,异时联体共生显著加速了老年小鼠的再生。单细胞转录组分析和谱系追踪分析揭示,老年门静脉周围肝细胞经历了短暂的体细胞重编程,以帮助肝细胞再填充。在机制上,我们发现这种重编程由年轻联体共生动物来源的淋巴毒素β(LTβ)/LTBR信号驱动。进一步分析确定年轻B细胞是关键效应细胞,因为这些细胞表现出肝脏浸润增加和LTβ表达升高,从而促进肝细胞重编程。此外,给予激动性LTBR抗体成功诱导了门静脉周围重编程,并加速了老年肝脏再生。年轻B细胞来源的LTβ通过LTβ/LTBR信号促进门静脉周围肝细胞的短暂体细胞重编程,从而促进老年肝脏再生。我们的研究强调了基于LTβ的策略在提高老龄人群再生方面的治疗潜力。肝脏的再生能力随年龄增长而下降,限制了老年供肝的利用。本研究表明,年轻的全身循环通过年轻B细胞来源的淋巴毒素β(LTβ)使老年肝脏再生恢复年轻,后者通过LTβ/LTBR信号诱导门静脉周围肝细胞的短暂体细胞重编程。这些发现对移植外科医生、肝病学家和衰老研究人员高度相关。在实践上,短期药物性LTBR激动作用可被临床医生用于治疗性地「预适应」老年供肝或增强老年患者肝切除后的再生。此外,我们的工作确立了异时移植作为一个强大的临床研究平台,用以研究实体器官的抗衰老机制和年轻化策略。

4胆管癌/胆道手术 (1篇)

基础研究 (1篇)

Seminars in cancer biology IF 20.3 2026-9-20 PMID: 42764109
Gastrointestinal (GI) cancers remain a leading cause of cancer mortality, with durable benefit from current therapies limited to a subset of patients. Precision oncology is expanding options by targeting recurrent, actionable alterations, most notably in cholangiocarcinoma (CCA), in genes such as FGFR2, IDH1, KRAS, BRAF and ERBB2. Here, we review the evolving therapeutic landscape, emphasizing clinical efficacy, and indications for various treatment modalities. Key therapies include FGFR inhibitors (first and next-generation; both covalent and FGFR2-selective agents), IDH1 inhibitors, KRAS and BRAF inhibitors combined with EGFR blockade and/or chemotherapy, and HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). Central mechanisms of both primary and secondary resistance are detailed, with a focus on on-target mutations and convergent off-target MAPK signaling pathways. Finally, we discuss drug-tolerant persister cells, residual tumor cell states that survive therapy without canonical genetic resistance alterations and may contribute to relapse and secondary resistance.
中文摘要:胃肠道(GI)肿瘤仍是癌症死亡的主要原因之一,当前治疗所能带来的持久获益仅限于一部分患者。精准肿瘤学通过靶向反复出现的可干预改变,正在拓展治疗选择,尤其是在胆管癌(CCA)中,涉及FGFR2、IDH1、KRAS、BRAF和ERBB2等基因。本文综述不断演变的治疗格局,重点讨论临床疗效及各种治疗方式的适应证。关键治疗包括FGFR抑制剂(第一代与下一代;共价及FGFR2选择性药物)、IDH1抑制剂、KRAS和BRAF抑制剂联合EGFR阻断和/或化疗,以及HER2靶向单克隆抗体、酪氨酸激酶抑制剂(TKI)和抗体药物偶联物(ADC)。文中详述原发性和继发性耐药的核心机制,重点关注靶点突变以及汇聚性的脱靶MAPK信号通路。最后,我们讨论药物耐受持留细胞,即一类在无经典遗传性耐药改变的情况下存活于治疗中的残余肿瘤细胞状态,并可能促成复发和继发性耐药。